Looks like the first test utilizing microRNA technology is close to clinical availability. Rosetta Genomics presented data last week in San Francisco highlighting a new way to screen for colon cancer using the new technology. The statistics are impressive: 91% sensitivity and 72% specificity. Colonoscopy is the current accepted standard for screening for colon cancer and sensitivity is "above 90%" with specificity at up to 99%. So the new test is probably less sensitive than a colonoscopy but a blood test to screen you for colon cancer is a lot more appealing to patients and can be done more frequently than an invasive procedure.